Clinical trials
Phase 1/2 Adenoviridae Infections trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Recruiting | 3 |
| Unknown status | 3 |
| Active, not recruiting | 2 |
| Terminated | 2 |
| Enrolling by invitation | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AlloVir | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Baylor College of Medicine | 1 |
| Beijing Bio-Targeting Therapeutics Technology Co., Ltd | 1 |
| Central Hospital, Nancy, France | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Crucell Holland BV | 1 |
| GeoVax, Inc. | 1 |
| George Papanicolaou Hospital | 1 |
| Hammond, H. Kirk, M.D. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adenoviridae Infections | 23 |
| Epstein-Barr Virus Infections | 8 |
| Cytomegalovirus Infections | 7 |
| Malaria, Falciparum | 2 |
| Prostatic Neoplasms | 2 |
| Virus Diseases | 2 |
| Glioma | 1 |
| Head and Neck Neoplasms | 1 |
| Heart Failure | 1 |
| Malaria | 1 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.